Loading
Xenotransplantation and Immune Response / Complement System in Diseases / Monoclonal and Polyclonal Antibodies Research · Journal article
Frontiers in Immunology · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review synthesizing current knowledge of complement C5a receptor biology in cancer, with particular focus on urothelial carcinoma. The authors note that C5aR1 appears tumor-promoting in urothelial carcinoma and is a described prognostic factor, while C5aR2 remains understudied in this malignancy despite an ambivalent role in other cancers. The work identifies C5aR2 as an unexplored target in urothelial carcinoma and frames complement-tumor crosstalk as relevant to precision medicine, but does not present new empirical evidence to resolve mechanistic questions.
Journal article. Patients with urothelial carcinoma (epidemiological context; no primary study population)..
Approximately 90–95% of urothelial carcinomas arise in the bladder; 5–10% in upper urinary tract. C5aR1 appears tumor-promoting by inhibiting T cell response and modulating the tumor microenvironment. C5aR2 plays an ambivalent role: counteracts tumor development in some mouse models while stimulating growth and chemoresistance in other cancer types.
No human clinical outcome data (response rate, survival, toxicity) provided for C5a receptor modulation in any cancer.
This review suggests that C5a receptor antagonism may warrant investigation as a precision medicine strategy in urothelial carcinoma, particularly targeting C5aR1 inhibition to restore T cell immunity. However, the ambivalent biology of C5aR2 and lack of clinical trial data mean treatment implications remain speculative.
This is a narrative review summarizing existing knowledge about complement C5a receptors in cancer, with limited new primary data on urothelial carcinoma; it raises mechanistic questions rather than reporting a rigorous empirical result.
Quoted from the source exactly as published.
This review suggests that C5a receptor antagonism may warrant investigation as a precision medicine strategy in urothelial carcinoma, particularly targeting C5aR1 inhibition to restore T cell immunity. However, the ambivalent biology of C5aR2 and lack of clinical trial data mean treatment implications remain speculative.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Urothelial carcinoma, the second most common urological malignancy, can arise in both the lower and upper urinary tract, with approximately 90–95% arising in the bladder, while urothelial carcinomas of the upper urinary tract account for only 5–10%. Treatment options depend on many factors, such as grade and risk factors, but include surgery, chemotherapy, and immunotherapy. Due to the unique pathological and molecular characteristics of each patient, some therapies are ineffective, and the need for targeted therapies and precision medicine is growing. The interactions of malignant cells within the tumor microenvironment can be decisive for the course of therapy. These interactions include components of the complement system, which is a highly conserved part of the innate immune system. The role of the complement system, especially the anaphylatoxin receptors C5aR1 and C5aR2, in cancer is complex. C5aR1 appears to be tumor-promoting by inhibiting the T cell response and modulating the TME, while C5aR2 plays an ambivalent role and was shown to counteract tumor development in some mouse models while in other types of cancer it stimulated tumor growth and led to chemoresistance. In urothelial carcinomas, C5aR1 has been described as a prognostic factor, while C5aR2 has not been considered to date. Here, we briefly summarize our current knowledge of the complex functions of C5a receptors in cancer. In particular, this is the first focused summary of data on C5a receptors in urothelial carcinomas.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.